Trial reportJournal of thrombosis and thrombolysis2011
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
Trial report in Journal of thrombosis and thrombolysis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Standard- versus extended-duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients.The Cochrane database of systematic reviews · 2024Pooled it
- Variation in Definitions of Immobility in Pharmacological Thromboprophylaxis Clinical Trials in Medical Inpatients: A Systematic Review.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Pooled it
- Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.Journal of thrombosis and thrombolysis · 2017Pooled it
- Pooled it
- Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients.Journal of the American Heart Association · 2021Trial
- Article
- Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: A comparative study.Research in social & administrative pharmacy : RSAP · 2022Article
- Challenges of extended venous thromboembolism prophylaxis in medical and surgical patients.Jornal vascular brasileiro · 2022Review
- Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients.Therapeutics and clinical risk management · 2021Review
- Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.TH open : companion journal to thrombosis and haemostasis · 2020Article
- Role of ambulation to prevent venous thromboembolism in medical patients: where do we stand?Jornal vascular brasileiro · 2019Review
- Intermittent pneumatic compression on top of pharmacological thromboprophylaxis in intensive care: added value or added cost?Journal of thoracic disease · 2019Article
- What has changed in venous thromboembolism prophylaxis for hospitalized patients over recent decades: review article.Jornal vascular brasileiro · 2019Review
- New Trends in Anticoagulation Therapy.The Surgical clinics of North America · 2018Review
- Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?Hematology. American Society of Hematology. Education Program · 2017Review
- Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer.Journal of thoracic disease · 2017Article
- Oral anticoagulants to reduce the risk of stroke in atrial fibrillation: how should a clinician choose?Clinical cardiology · 2013Review
- An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.Journal of the American Heart Association · 2013Review
- Novel anticoagulant use for venous thromboembolism: a 2013 update.Current treatment options in cardiovascular medicine · 2013Article
- Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.Vascular health and risk management · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with acute medical illnesses are at increased risk of venous thromboembolism (VTE), a significant cause of morbidity and mortality. Thromboprophylaxis is recommended in these patients but questions remain regarding the optimal duration of therapy. The aim of this study is to determine whether oral rivaroxaban is non-inferior to standard-duration (approximately 10 days) subcutaneous (s.c.) enoxaparin for the prevention of VTE in acutely ill medical patients, and whether extended-duration (approximately 5 weeks) rivaroxaban is superior to standard-duration enoxaparin. Patients aged 40 years or older and hospitalized for various acute medical illnesses with risk factors for VTE randomly receive either s.c. enoxaparin 40 mg once daily (od) for 10 ± 4 days or oral rivaroxaban 10 mg od for 35 ± 4 days. The primary efficacy outcomes are the composite of asymptomatic proximal deep vein thrombosis (DVT), symptomatic DVT, symptomatic non-fatal pulmonary embolism (PE), and VTE-related death up to day 10 + 4 and up to day 35 + 4. The primary safety outcome is the composite of treatment-emergent major bleeding and clinically relevant non-major bleeding. As of July 2010, 8,101 patients from 52 countries have been randomized. These patients have a broad range of medical conditions: approximately one-third were diagnosed with acute heart failure, just under one-third were diagnosed with acute infectious disease, and just under one-quarter were diagnosed with acute respiratory insufficiency. MAGELLAN will determine the efficacy, safety, and pharmacological profile of oral rivaroxaban for the prevention of VTE in a diverse population of medically ill patients and the potential of extended-duration therapy to reduce incidence of VTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.